Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Receivables (2023 - 2025)

Fennec Pharmaceuticals filings provide 3 years of Change in Receivables readings, the most recent being $3.5 million for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 1876.0% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.4 million, a 58.01% increase, with the full-year FY2025 number at $12.4 million, up 58.01% from a year prior.
  • Change in Receivables hit $3.5 million in Q4 2025 for Fennec Pharmaceuticals, up from $3.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $5.3 million in Q1 2025 to a low of $138000.0 in Q1 2023.
  • Median Change in Receivables over the past 3 years was $2.1 million (2023), compared with a mean of $2.3 million.
  • Biggest five-year swings in Change in Receivables: tumbled 95.92% in 2024 and later surged 1876.0% in 2025.
  • Fennec Pharmaceuticals' Change in Receivables stood at $4.3 million in 2023, then crashed by 95.92% to $175000.0 in 2024, then surged by 1876.0% to $3.5 million in 2025.
  • The last three reported values for Change in Receivables were $3.5 million (Q4 2025), $3.4 million (Q3 2025), and $265000.0 (Q2 2025) per Business Quant data.